Home » Newsletters » BioWorld Science

BioWorld Science

June 18, 2010

View Archived Issues

Novel DNA-alkylating agents described by Syntarga

Novel PI3K inhibitors presented by Shionogi

Kowa describes novel JAK inhibitors

Merck & Co. claims new antihypertensive agents

Cardiolynx patents new nitrate esters of valsartan and cilostazol

Long-term pimavanserin safe and well tolerated in Parkinson's disease psychosis

Pramipexole ER shows long-term efficacy and safety in advanced Parkinson's disease

GIND and ISB join to identify genes and targets involved in Huntington's disease

Milatuzumab-doxorubicin conjugate enters phase I/II trial in MM

Catena demonstrates visual benefits in Leber's hereditary optic neuropathy

TX-RAD completes preclinical development for inflammatory arthritis

Final phase II data on voreloxin/cytarabine in AML support phase III testing

SRX-251 shows favorable safety, tolerability and pharmacokinetics in healthy subjects

AZD-6244 is beneficial in phase II trial in IRPTC and PTC

CEP cells show promise as biomarker for response to antiangiogenic therapy in CRPC

Abbott and Neurocrine join to develop elagolix for endometriosis

Safety monitoring board recommends continuation of phase III Allovectin-7 trial

Durect reports on phase IIb hysterectomy trial of Posidur

Akebia's HIF-PH inhibitor AKB-6548 effective in phase Ib trial

Phase IIa trial of NU-1618 in hyperuricemia meets primary endpoint

Phase II trial of GDC-0449 in colorectal cancer does not meet primary endpoint

EMD Serono resumes BLP-25 liposome vaccine program in lung cancer

OBI-1 obtains positive opinion for orphan drug status in Europe

OncoMed and Bayer Schering form anticancer stem cell alliance

Thallion closes phase II TLN-232 trial following arbitral tribunal decision

Relypsa begins phase II trial of RLY-5016 for hyperkalemia

FDA approves Jevtana for metastatic hormone-refractory prostate cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Hippocratic loath? ‘Harm’ threat from ACIP’s proposed HBV shift
BioWorld
Individual liberty and choice vs. wider public health became one predictable hinge upon which swung the often-acerbic debates at the CDC’s Advisory Committee for...
Høeg appointment as acting CDER director tied to vaccine strategy?
BioWorld
After a more than 13-year period of stability with Janet Woodcock as the head of CDER, with Patrizia Cavazzoni taking charge during the next four years of former...
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...